The Akt signaling pathway: An emerging therapeutic target in malignant melanoma

Cancer Biology and Therapy

Volumn 12, Issue 12, 2011, Pages 1032-1049

  Madhunapantula, SubbaRao V ^a,b   Mosca, Paul J ^d   Robertson, Gavin P ^a,b,c  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Akt3; Apoptosis; Melanoma; Oncogene; PI3K; PTEN; Tumorigenesis

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; A 423795; A 443654; ANTINEOPLASTIC AGENT; API 2; BI 69 A11; BI 69A11; CHLOROETHYLNITROSOUREA; EDELFOSINE; EVEROLIMUS; GSJ 690693; HEXAMETHYLENEBISACETAMIDE; ISC 4; ISOSELENOCYANATE 4; KP 372; MILTEFOSINE; NSC 177223; NVP BAG 956; NVP BBD 130; OXA 01; PERIFOSINE; PHT 427; PROTEIN KINASE B; PX 316; RAPAMYCIN; RILUZOLE; SERTRALINE; SORAFENIB; SRI 13668; TANESPIMYCIN; TEMSIROLIMUS; TRICIRIBINE; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLON CANCER; COLORECTAL CANCER; DIZZINESS; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; LUNG CANCER; MELANOMA; NEUROTOXICITY; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PANCREAS TUMOR; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; THROMBOCYTOPENIA; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84055199840     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.12.18442     Document Type: Review

References (201)

1. Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 2008; 68:5-8; PMID:18172288; http://dx.doi.org/10.1158/0008-5472.CAN-07-2038
2. Madhunapantula SV, Robertson GP. The PTENAKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2009; 22:400-19; PMID:19493313; http://dx.doi.org/10.1111/ j.1755-148X.2009.00585.x
3. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 2005; 24:273-85; PMID:15986137; http://dx.doi.org/10.1007/s10555-005-1577-9
4. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol 2010; 80:624-37; PMID:20450891; http://dx.doi.org/ 10.1016/j.bcp.2010.04.029
5. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003; 63:2881-90; PMID:12782594
6. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64:7002-10; PMID:15466193; http://dx.doi.org/10.1158/0008-5472.CAN-04- 1399
7. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261-74; PMID: 17604717; http://dx.doi.org/10.1016/j.cell.2007.06.009
8. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010; 10:342-52; PMID:20414202; http://dx.doi.org/10. 1038/nrc2842
9. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16:34-44; PMID:20214616; http:// dx.doi.org/10.2174/138161210789941865
10. Lazo JS, Wipf P. Phosphatases as targets for cancer treatment. Curr Opin Investig Drugs 2009; 10:1297-304; PMID:19943201
11. Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 2005; 1059:16-25; PMID: 16382039; http://dx.doi.org/10.1196/annals.1339.005
12. Hsu MY, Meier F, Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002; 70:522-36; PMID:12492494; http://dx.doi.org/10.1046/j.1432-0436.2002.700906.x
13. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005; 115:813-24; PMID:15841168
14. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 2007; 67:3626-36; PMID:17440074; http://dx.doi.org/10.1158/0008-5472.CAN-06-4234
15. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 2005; 23:1473-82; PMID:15735123; http://dx.doi.org/10.1200/JCO.2005.07.168
16. Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, et al. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res 2009; 15:3029-36; PMID:19383818; http://dx.doi.org/10.1158/1078-0432.CCR-08- 2768
17. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62; PMID:19629070; http://dx.doi.org/10.1038/nrc2664
18. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346:561-76; PMID:10698680; http://dx.doi.org/10. 1042/0264-6021:3460561
19. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009; 37:217-22; PMID:19143635; http:// dx.doi.org/10.1042/BST0370217
20. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7:e38; PMID:19209957; http://dx.doi.org/10.1371/journal. pbio.1000038
21. Zheng Y, Peng M, Wang Z, Asara JM, Tyner AL. Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol 2010; 30:4280-92; PMID: 20606012; http://dx.doi.org/10.1128/MCB.00024-10
22. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999; 99:323-34; PMID:10555148; http://dx.doi.org/10.1016/S0092-8674(00)81663-3
23. Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999; 9:125-8; PMID:10203785; http://dx.doi.org/10.1016/S0962-8924(99)01519-6
24. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002; 70:829-44; PMID:11875759; http://dx.doi.org/10.1086/340026
25. Gericke A, Munson M, Ross AH. Regulation of the PTEN phosphatase. Gene 2006; 374:1-9; PMID: 16675164; http://dx.doi.org/10.1016/j.gene.2006.02.024
26. Guldberg P. thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/ PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997; 57:3660-3; PMID:9288767
27. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998; 16:3397-402; PMID:9692547; http://dx.doi.org/10.1038/sj.onc.1201881
28. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011; 71:2750-60; PMID:21317224; http://dx.doi.org/10.1158/0008-5472.CAN-10-2954
29. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. Deregulated Akt3 Activity Promotes Development of Malignant Melanoma. Cancer Res 2004. In press. PMID:15466193; http://dx.doi.org/10.1158/0008-5472.CAN-04- 1399
30. Mikhail M, Velazquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L, et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 2005; 11:5153-7; PMID:16033830; http://dx.doi.org/10.1158/1078-0432.CCR-05-0397
31. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, Jr, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41:544-52; PMID: 19282848; http://dx.doi.org/10.1038/ng.356
32. Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 2010; 29:6222-32; PMID:20711233; http://dx.doi.org/10.1038/ onc.2010.349
33. Mounir Z, Krishnamoorthy JL, Robertson GP, Scheuner D, Kaufman RJ, Georgescu MM, et al. Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway. Sci Signal 2009; 2:ra85; PMID:20029030; http://dx.doi. org/10.1126/scisignal.2000389
34. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96:4240-5; PMID: 10200246; http://dx.doi.org/10.1073/ pnas.96.8.4240
35. Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007; 102:1368-74; PMID: 17972252; http://dx.doi.org/10.1002/jcb.21593
36. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999; 96:2110-5; PMID:10051603; http://dx.doi.org/10.1073/pnas.96.5.2110
37. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003; 22:3113-22; PMID: 12789288; http://dx.doi.org/10.1038/sj.onc.1206451
38. Huang W, Chang HY, Fei T, Wu H, Chen YG. GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 2007; 26:2471- 82; PMID:17043650; http://dx.doi.org/10.1038/sj. onc.1210033
39. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4:988-1004; PMID:16341064; http://dx.doi.org/10.1038/nrd1902
40. Franke TF. PI3K/Akt: getting it right matters. Oncogene 2008; 27:6473-88; PMID:18955974; http://dx.doi.org/ 10.1038/onc.2008.313
41. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784:159-85; PMID:17997386
42. Fruman DA. Regulatory subunits of class IA PI3K. Curr Top Microbiol Immunol 2010; 346:225-44; PMID: 20563711; http://dx.doi.org/10.1007/82-2010-39
43. Vogt PK, Gymnopoulos M, Hart PI, Jr.3-kinase and cancer: changing accents. Curr Opin Genet Dev 2009; 19:12-7; PMID:19185485; http://dx.doi.org/10. 1016/ j.gde.2008.11.011
44. Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, et al. Vertical targeting of the phosphatidylinositol- 3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 2010; 16:6029-39; PMID:21169255; http://dx.doi.org/10.1158/1078-0432.CCR-10-1490
45. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98:10983-5; PMID:11572954; http://dx.doi.org/10.1073/ pnas.211430998
46. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14:381-95; PMID:11882383; http://dx. doi.org/10.1016/S0898-6568(01)00271-6
47. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997; 89:457-67; PMID:9150145; http://dx.doi.org/10.1016/S0092- 8674(00)80226-3
48. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI (3)K and PKB. Nature 1997; 385:544-8; PMID: 9020362; http://dx.doi.org/10.1038/385544a0
49. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003; 22:3087-91; PMID:12789285; http://dx.doi.org/10.1038/sj.onc.1206449
50. Werzowa J, Koehrer S, Strommer S, Cejka D, Fuereder T, Zebedin E, et al. Vertical inhibition of the mTORC1/ mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol 2011; 131:495-503; PMID:21048785; http://dx.doi.org/10.1038/jid.2010.327
51. Tachiiri S, Sasai K, Oya N, Hiraoka M. Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses. Jpn J Cancer Res 2000; 91:1314-8; PMID:11123431; http://dx.doi.org/10.1111/j.1349- 7006.2000.tb00919.x
52. Harfouche R, Basu S, Soni S, Hentschel DM, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 2009; 12:325-38; PMID:19685150; http://dx.doi.org/10.1007/s10456- 009-9154-4
53. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell 2002; 111:293- 303; PMID:12419241; http://dx.doi.org/10.1016/ S0092-8674(02)01083-8
54. Scheid MP, Woodgett JR. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001; 2:760-8; PMID:11584303; http://dx.doi.org/10.1038/ 35096067
55. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003; 546:108-12; PMID:12829245; http://dx.doi.org/10. 1016/S0014-5793(03)00562-3
56. Bellacosa A, Testa JR, Moore R, Larue L. A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther 2004; 3:268-75; PMID:15034304; http://dx.doi.org/ 10.4161/cbt.3.3.703
57. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29:233-42; PMID:15130559; http:// dx.doi.org/10.1016/j.tibs.2004.03.006
58. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001; 26:657-64; PMID:11701324; http://dx.doi.org/ 10.1016/S0968-0004(01)01958-2
59. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13:2905-27; PMID: 10579998; http://dx.doi.org/10.1101/gad. 13.22.2905
60. Lietzke SE, Bose S, Cronin T, Klarlund J, Chawla A, Czech MP, et al. Structural basis of 3-phosphoinositide recognition by pleckstrin homology domains. Mol Cell 2000; 6:385-94; PMID:10983985; http://dx.doi.org/ 10.1016/S1097-2765(00)00038-1
61. Ferguson KM, Kavran JM, Sankaran VG, Fournier E, Isakoff SJ, Skolnik EY, et al. Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains. Mol Cell 2000; 6:373-84; PMID:10983984; http://dx.doi.org/10. 1016/S1097- 2765(00)00037-X
62. Jones PF, Jakubowicz T, Hemmings BA. Molecular cloning of a second form of rac protein kinase. Cell Regul 1991; 2:1001-9; PMID:1801921
63. Andjelković M, Jones PF, Grossniklaus U, Cron P, Schier AF, Dick M, et al. Developmental regulation of expression and activity of multiple forms of the Drosophila RAC protein kinase. J Biol Chem 1995; 270:4066-75; PMID:7876156; http://dx.doi.org/10.1074/jbc.270.8.4066
64. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15:6541-51; PMID:8978681
65. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 2008; 68:3429-39; PMID:18451171; http://dx.doi. org/10.1158/0008-5472.CAN-07-5867
66. Konishi H, Kuroda S, Tanaka M, Matsuzaki H, Ono Y, Kameyama K, et al. Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun 1995; 216:526-34; PMID:7488143; http://dx.doi.org/10.1006/bbrc.1995.2654
67. Brodbeck D, Hill MM, Hemmings BA. Two splice variants of protein kinase B gamma have different regulatory capacity depending on the presence or absence of the regulatory phosphorylation site serine 472 in the carboxyl-terminal hydrophobic domain. J Biol Chem 2001; 276:29550-8; PMID:11387345; http://dx.doi.org/10.1074/jbc.M104633200
68. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Top Microbiol Immunol 2010; 346:31-56; PMID:20517722; http://dx.doi.org/ 10.1007/82-2010-58
69. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010; 2:19-42; PMID:20182580
70. Yang WL, Wu CY, Wu J, Lin HK. Regulation of Akt signaling activation by ubiquitination. Cell Cycle 2010; 9:487-97; PMID:20081374; http://dx.doi.org/ 10.4161/cc.9.3.10508
71. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009; 8:2502-8; PMID:19597332; http://dx.doi.org/10. 4161/cc.8.16.9335
72. Guénin S, Schwartz L, Morvan D, Steyaert JM, Poignet A, Madelmont JC, et al. PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. Int J Oncol 2008; 32:49-57; PMID:18097542
73. Andrabi S, Gjoerup OV, Kean JA, Roberts TM, Schaffhausen B. Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc Natl Acad Sci USA 2007; 104:19011-6; PMID:18006659; http://dx.doi.org/10.1073/pnas.0706696104
74. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18: 13-24; PMID:15808505; http://dx.doi.org/10.1016/j. molcel.2005.03.008
75. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009; 325:1134-8; PMID:19713527; http://dx.doi.org/10.1126/science.1175065
76. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448:439-44; PMID:17611497; http:// dx.doi.org/10.1038/nature05933
77. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008; 99:1265-8; PMID:18813315; http://dx.doi.org/10.1038/sj.bjc.6604637
78. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007; 12:104-7; PMID:17692802; http://dx.doi.org/10.1016/j. ccr.2007.07.014
79. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010; 29:150-5; PMID:19802009; http://dx.doi.org/10.1038/onc.2009.315
80. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995; 270:27489-94; PMID: 7499206; http://dx.doi.org/10.1074/jbc.270.46.27489
81. Obata T, Yaffe MB, Leparc GG, Piro ET, Maegawa H, Kashiwagi A, et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem 2000; 275:36108-15; PMID:10945990; http:// dx.doi.org/10.1074/jbc.M005497200
82. Rosner M, Hanneder M, Freilinger A, Hengstschlager M. Nuclear/cytoplasmic localization of Akt activity in the cell cycle. Amino Acids 2007; 32:341-5; PMID:17357828; http://dx.doi.org/10.1007/s00726-007-0509-0
83. Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005; 17:150-7; PMID:15780591; http://dx.doi.org/10.1016/j. ceb.2005.02.010
84. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30:193-204; PMID:15023437; http://dx.doi.org/10.1016/j.ctrv.2003.07.007
85. Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 2003; 278:10189-94; PMID:12524439; http://dx.doi.org/10.1074/jbc. M210837200
86. Wang L, Harris TE, Roth RA, Lawrence JC, Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 2007; 282:20036-44; PMID:17510057; http:// dx.doi.org/10.1074/jbc. M702376200
87. Ikenoue T, Kanai F, Hikiba Y, Tanaka Y, Imamura J, Ohta M, et al. Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers. Mol Carcinog 2005; 43:59-63; PMID: 15791648; http://dx.doi.org/10.1002/mc.20102
88. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132:363-74; PMID:18267069; http://dx.doi.org/10.1016/ j.cell.2007.12.032
89. Houben R, Ortmann S, Drasche A, Troppmair J, Herold MJ, Becker JC. Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation. J Invest Dermatol 2009; 129:406-14; PMID:18650848; http://dx.doi.org/10.1038/jid.2008.214
90. Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 2009; 28:2289-98; PMID:19398955; http://dx.doi. org/10.1038/onc.2009.95
91. Yang J, Splittgerber R, Yull FE, Kantrow S, Ayers GD, Karin M, et al. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest 2010; 120:2563-74; PMID:20530876; http://dx.doi. org/10.1172/JCI42358
92. Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer 2009; 125:2863-70; PMID:19609947; http://dx.doi.org/10.1002/ijc.24748
93. Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, et al. Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates. Clin Cancer Res 2009; 15:1674-85; PMID:19208796; http://dx.doi.org/10.1158/1078-0432. CCR-08-2214
94. LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anticancer Drugs 2007; 18:861-74; PMID:17667591
95. Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009; 11:102-10; PMID:19216841; http://dx.doi.org/10.1007/s11912- 009-0016-4
96. Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005; 23:569-75; PMID:16034524; http://dx.doi.org/10. 1007/s10637- 005-1157-4
97. Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA, et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 2004; 64:2782-92; PMID:15087394; http://dx.doi.org/10.1158/0008-5472.CAN-03-1530
98. Gills JJ, Dennis PA. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/ threonine kinase, Akt. Expert Opin Investig Drugs 2004; 13:787-97; PMID:15212619; http://dx.doi.org/ 10.1517/13543784.13.7.787
99. Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Willìams R, et al. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 2004; 14:513-27; PMID:15559765
100. Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, et al. Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J Med Chem 2008; 51:7820-6; PMID: 19053750; http://dx.doi.org/10.1021/jm800993r
101. Nguyen N, Sharma A, Nguyen N, Sharma AK, Desai D, Huh SJ, et al. Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev Res (Phila) 2011; 4:248-58; PMID:21097713; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0106
102. Madhunapantula SV, Desai D, Sharma A, Huh S, Amin S, Robertson GP. PBIse, a novel selenium containing drug for the treatment of malignant melanoma. Mol Cancer Ther 2008; 7:1297-308; PMID:18483317; http://dx.doi.org/10.1158/1535- 7163.MCT-07-2267
103. Desai D, Madhunapantula SV, Gowdahalli K, Sharma A, Chandagaludoreswamy R, El-Bayoumy K, et al. Synthesis and characterization of a novel iNOS/ Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl) bisisoselenourea (PBISe)-against colon cancer. Bioorg Med Chem Lett 2010; 20:2038-43; PMID:20153642; http://dx.doi.org/10.1016/j.bmcl.2009.09.071
104. Chung CY, Madhunapantula SV, Desai D, Amin S, Robertson GP. Melanoma Prevention Using Topical PBISe. Cancer Prev Res (Phila) 2011.
105. Reddy BS, Rivenson A, Kulkarni N, Upadhyaya P, el-Bayoumy K. Chemoprevention of colon carcinogenesis by the synthetic organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Cancer Res 1992; 52:5635-40; PMID:1394188
106. Tanaka T, Kohno H, Murakami M, Kagami S, El-Bayoumy K. Suppressing effects of dietary supplementation of the organoselenium 1,4-phenylenebis (methylene)selenocyanate and the Citrus antioxidant auraptene on lung metastasis of melanoma cells in mice. Cancer Res 2000; 60:3713-6; PMID:10919638
107. Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, et al. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res 2009; 69:5073-81; PMID:19491272; http://dx. doi.org/10.1158/0008-5472.CAN-08-3839
108. Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide- dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther 2010; 9:706-17; PMID:20197390; http://dx.doi.org/10. 1158/1535-7163.MCT-09-0985
109. Kim D, Sun M, He L, ZhouQH, Chen J, SunXM, et al. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J Biol Chem 2010; 285:8383-94; PMID:20068047; http://dx. doi.org/10.1074/jbc.M109.094060
110. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004; 64:4394-9; PMID:15231645; http://dx.doi.org/10.1158/0008-5472.CAN-04-0343
111. Schweinsberg PD, Smith RG, Loo TL. Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020). Biochem Pharmacol 1981; 30:2521-6; PMID:7306204; http://dx.doi.org/10.1016/0006- 2952(81)90577-3
112. Feun LG, Blessing JA, Barrett RJ, Hanjani P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am J Clin Oncol 1993; 16:506-8; PMID:8256767; http://dx.doi.org/10.1097/00000421-199312000-00010
113. Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, Ajani JA, et al. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res 1984; 44:3608-12; PMID:6744283
114. Tang HJ, Jin X, Wang S, Yang D, Cao Y, Chen J, et al. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol Oncol 2006; 100:308-17; PMID:16209885; http://dx.doi.org/10.1016/j.ygyno.2005.08.044
115. Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, et al. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 2006; 5:637-44; PMID:16546978; http://dx.doi.org/10.1158/1535-7163.MCT-05-0453
116. Gaitonde S, De SK, Tcherpakov M, Dewing A, Yuan H, Riel-Mehan M, et al. BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res 2009; 22:187-95; PMID:19175524; http://dx.doi.org/ 10.1111/j.1755-148X.2009.00544.x
117. Lin X, Murray JM, Rico AC, Wang MX, Chu DT, Zhou Y, et al. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg Med Chem Lett 2006; 16:4163-8; PMID:16765046; http://dx.doi.org/10.1016/j.bmcl.2006.05.092
118. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005; 4:977-86; PMID:15956255; http://dx.doi.org/10.1158/1535- 7163.MCT-05-0005
119. Morgan-Lappe S, Woods KW, Li Q, Anderson MG, Schurdak ME, Luo Y, et al. RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene 2006; 25:1340-8; PMID: 16247451; http://dx.doi.org/10.1038/sj.onc.1209169
120. Shi Y, Liu X, Han EK, Guan R, Shoemaker AR, Oleksijew A, et al. Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. Neoplasia 2005; 7:992-1000; PMID:16331885; http://dx.doi.org/10.1593/neo.05355
121. Han EK, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 2007; 26:5655-61; PMID:17334390; http://dx.doi.org/10.1038/sj.onc.1210343
122. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008; 68:2366-74; PMID:18381444; http://dx.doi.org/10.1158/0008-5472.CAN-07-5783
123. Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, et al. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55: 1329-37; PMID:20740623; http://dx.doi.org/10.1002/pbc.22710
124. Dey A, Wong E, KuaN, Teo HL, Tergaonkar V, Lane D. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle 2008; 7:3759-67; PMID:19029824; http://dx.doi. org/10.4161/cc.7.23.7213
125. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiationinducing agent. Blood 1992; 80:2604-9; PMID: 1421378
126. Reddy KK, Lefkove B, Chen LB, Govindarajan B, Carracedo A, Velasco G, et al. The antidepressant sertraline downregulates Akt and has activity against melanoma cells. Pigment Cell Melanoma Res 2008; 21:451-6; PMID:18710373; http://dx.doi.org/10.1111/j.1755-148X.2008.00481.x
127. Proud CG. mTOR Signalling in Health and Disease. Biochem Soc Trans 2011; 39:431-6; PMID:21428914; http://dx.doi.org/10.1042/BST0390431
128. Roychowdhury A, Sharma R, Kumar S. Recent advances in the discovery of small molecule mTOR inhibitors. Future Med Chem 2010; 2:1577-89; PMID:21426150; http://dx.doi.org/10.4155/fmc.10.233
129. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26:1932-40; PMID:17001314; http://dx.doi. org/10.1038/sj.onc.1209990
130. Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, Cmiljanovic V, et al. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 2009; 7:601-13; PMID:19372588; http://dx.doi.org/10.1158/1541-7786.MCR-08-0366
131. Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, et al. Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors. Cancer Res 2011; 71:1573-83; PMID: 21363918; http://dx.doi.org/10.1158/0008-5472. CAN-10-3126
132. Maira SM, Furet P, Stauffer F. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. Future Med Chem 2009; 1:137-55; PMID: 21426073; http://dx.doi.org/10.4155/fmc.09.5
133. Heron-Milhavet L, Khouya N, Fernandez A, Lamb NJ. Akt1 and Akt2: Differentiating the aktion. Histol Histopathol 2011; 26:651-62; PMID:21432781
134. Yoeli-Lerner M, Chin YR, Hansen CK, Toker A. Akt/ protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res 2009; 7:425-32; PMID:19258413; http://dx.doi.org/10.1158/1541-7786.MCR-08-0342
135. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-51; PMID: 12789290; http://dx.doi.org/10.1038/sj.onc.1206454
136. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, et al. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res 2008; 68:7638-49; PMID:18794153; http://dx.doi. org/10.1158/0008-5472.CAN-07-6614
137. Gaitonde S, De SK, Tcherpakov M, et al. BI-69A11- mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res 2009.
138. Kapetanovic IM, Muzzio M, Hu SC, Crowell JA, Rajewski RA, Haslam JL, et al. Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys. Cancer Chemother Pharmacol 2010; 65:1109-16; PMID: 19756605; http://dx.doi.org/10.1007/s00280-009- 1116-4
139. Chao WR, Yean D, Amin K, Green C, Jong L. Computer-aided rational drug design: a novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling. J Med Chem 2007; 50:3412-5; PMID: 17602463; http://dx.doi.org/10.1021/jm070040e
140. Vasudevan KM, Garraway LA. AKT signaling in physiology and disease. Curr Top Microbiol Immunol 2010; 347:105-33; PMID:20549472; http://dx.doi. org/10.1007/82-2010-66
141. Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R, et al. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther 2010; 9:493-503; PMID:20139722; http://dx.doi.org/10.4161/cbt.9.7.11100
142. Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, et al. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 2009; 15:217-25; PMID:19118049; http://dx.doi.org/10.1158/1078-0432. CCR-08-1253
143. Sudarsanam S, Johnson DE. Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel 2010; 13:31-40; PMID:20047144
144. Tan K, Kimber WA, Luan J, et al. Analysis of genetic variation in Akt2/PKB-beta in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes. Diabetes 2007; 56:714-9; PMID: 17327441; http://dx.doi.org/10.2337/db06-0921
145. Sofroniadou S, Goldsmith D. Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf 2011; 34:97-115; PMID:21247219; http://dx.doi.org/ 10.2165/11585040- 000000000-00000
146. Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2006; 24:435-9; PMID:16528479; http://dx.doi.org/10.1007/s10637- 006-6406-7
147. Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neurooncol 2010; 12:608-13; PMID:20156802; http://dx. doi.org/10.1093/neuonc/nop070
148. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28:1408-14; PMID:20142598; http://dx.doi.org/10.1200/JCO.2009.24.0994
149. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20:1674-81; PMID: 19549709; http://dx.doi.org/10.1093/annonc/mdp060
150. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010; 10:368; PMID:20630061; http://dx.doi. org/10.1186/1471-2407-10-368
151. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010; 117:473-6; PMID:20347480; http://dx.doi.org/ 10.1016/j.ygyno.2010.02.022
152. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23:5294-304; PMID:15998902; http:// dx.doi.org/10.1200/JCO.2005.23.622
153. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-22; PMID: 15955899; http://dx.doi.org/10.1200/JCO.2005.66. 130
154. Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, Jeong JH, et al. Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol 2010; 28:2974-81; PMID:20479407; http://dx.doi.org/10.1200/JCO.2009.26.1602
155. Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LX, et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 2008; 19:315-20; PMID:17804473; http://dx. doi.org/10.1093/annonc/mdm429
156. Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, et al. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 2006; 42:629-35; PMID:16464571; http://dx.doi.org/10.1016/j.ejca.2005.11.025
157. Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002; 38:1615-21; PMID:12142051; http://dx.doi.org/10.1016/S0959-8049(02)00127-2
158. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004; 10:7450-6; PMID:15569974; http://dx.doi. org/10.1158/1078-0432.CCR-03-0406
159. Bailey HH, Mahoney MR, Ettinger DS, Maples WJ, Fracasso PM, Traynor AM, et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 2006; 107:2462-7; PMID:17058289; http://dx.doi.org/10. 1002/cncr.22308
160. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007; 13:7421-31; PMID:18094426; http://dx.doi.org/10.1158/1078-0432.CCR-07-0760
161. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006; 5:766-70; PMID: 16760642; http://dx.doi.org/10.4161/cbt.5.7.2874
162. Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, Albrecht S, et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res 2010; 70:2548-57; PMID:20197468; http://dx.doi. org/10.1158/0008-5472.CAN-09-2503
163. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010; 19:1355-66; PMID: 20846000; http://dx.doi.org/10.1517/13543784.2010.520701
164. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107:4053-62; PMID:16418332; http:// dx.doi.org/10.1182/blood-2005-08-3434
165. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005; 65:7429-35; PMID:16103096; http://dx.doi.org/10.1158/0008-5472.CAN-05-1042
166. Terwogt JM, Mandjes IA, Sindermann H, Beijnen JH, ten Bokkel Huinink WW. Phase II trial of topically applied miltefosine solution in patients with skinmetastasized breast cancer. Br J Cancer 1999; 79:1158- 61; PMID:10098751; http://dx.doi.org/10.1038/sj.bjc.6690184
167. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90- geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997; 89:239-50; PMID: 9108479; http://dx.doi.org/10.1016/S0092-8674(00) 80203-2
168. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97:10832-7; PMID:10995457; http://dx.doi. org/10.1073/pnas.170276797
169. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006; 103:57-62; PMID:16371460; http://dx.doi.org/10.1073/pnas.0609973103
170. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, et al. Phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008; 14:8302-7; PMID: 19088048; http://dx.doi.org/ 10.1158/1078-0432.CCR- 08-1002
171. Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, et al. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res 2003; 9:2887-92; PMID:12912932
172. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005; 104:1045-8; PMID: 16007689; http://dx.doi.org/10.1002/ cncr.21265
173. Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 2006; 29:352-60; PMID:16891861; http:// dx.doi.org/10.1097/01.coc.0000217877.78473.a4
174. Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006; 40:261-9; PMID:16418322; http://dx.doi.org/10.1345/aph.1G387
175. Spector NL, Xia W, Burris H, 3rd, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23:2502-12; PMID:15684311; http://dx. doi.org/10.1200/JCO.2005.12.157
176. Swash M. New ideas for therapy in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 3-4; PMID:16036419; http://dx.doi.org/10.1080/ 14660820510035379
177. Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, et al. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res 2011; 17:1807-14; PMID:21325066; http://dx.doi.org/10. 1158/1078-0432.CCR-10-1276
178. Marín YE, Namkoong J, Cohen-Solal K, Shin SS, Martino JJ, Oka M, et al. Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal 2006; 18:1279-86; PMID:16305822; http://dx.doi.org/10.1016/j.cellsig.2005.10.012
179. Namkoong J, Shin SS, Lee HJ, Marín YE, Wall BA, Goydos JS, et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 2007; 67:2298-305; PMID:17332361; http://dx. doi.org/10.1158/0008- 5472.CAN-06-3665
180. Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A, et al. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 2009; 15:3896-902; PMID:19458050; http://dx.doi. org/10.1158/1078-0432.CCR- 08-3303
181. Cheng Y, Ren X, Zhang Y, Patel R, Sharma A, Wu H, et al. eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206. Cancer Res 2011; 71:2654-63; PMID:21307130; http://dx.doi.org/10.1158/0008-5472.CAN-10-2889
182. Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, et al. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs 2011; 29:1381-9; PMID:20644979; http://dx.doi.org/10.1007/s10637-010-9479-2
183. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335- 42; PMID:15175435; http://dx.doi.org/10.1056/ NEJMoa032691
184. López-Fauqued M, Gil R, Grueso J, Hernandez-Losa J, Pujol A, et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int J Cancer 2010; 126:1549-61; PMID: 19810100
185. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008; 128:2013-23; PMID: 18323781; http://dx.doi.org/10.1038/jid.2008. 44
186. Sinnberg T, Lasithiotakis K, Niessner H, et al. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 2009; 129:1500-15; PMID:19078992; http://dx.doi.org/10.1038/ jid.2008.379
187. Pópulo H, Soares P, Rocha AS, Silva P, Lopes JM. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 2010; 20:107-17; PMID:20173664; http://dx.doi.org/10.1097/CMR.0b013e32832ccd09
188. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 2010; 70:6670-81; PMID:20647317; http://dx. doi.org/10.1158/0008-5472.CAN-09-4471
189. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010; 467:596-9; PMID: 20823850; http://dx.doi.org/10.1038/nature09454
190. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011
191. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/NEJMoa0804385
192. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427-30; PMID:20179705; http:// dx.doi.org/10.1038/nature08902
193. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968-72; PMID: 21107320; http://dx.doi.org/10.1038/nature09627
194. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-7; PMID: 21107323; http://dx.doi.org/10.1038/nature09626
195. Gopal YN, Deng W, Woodman SE, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010; 70:8736-47; PMID:20959481; http://dx. doi.org/10.1158/0008-5472.CAN-10-0902
196. Chang TT, Chou TC. Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr Taiwan 2000; 41:294-302; PMID:11198934
197. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 2008; 14:3571-81; PMID:18519791; http://dx. doi.org/10.1158/1078-0432.CCR-07-4881
198. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010; 16:530-40; PMID:20068094; http://dx.doi.org/10.1158/1078-0432.CCR-09-0816
199. Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res 2010. In press. PMID:20216471
200. Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, et al. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol 2007; 224:300-7; PMID:17208263; http:// dx.doi.org/10.1016/j.taap.2006.11.021
201. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466